What is AI-Driven Cyclic Peptide Design?
Our platform combines artificial intelligence with proven peptide discovery concepts to create a next-generation cyclic peptide drug discovery engine. By integrating deep learning models with high-throughput mRNA display screening, we can explore vast libraries of macrocyclic peptides incorporating both canonical and non-canonical amino acids. The AI models predict binding affinity, selectivity, and pharmacokinetic properties, while wet-lab validation ensures rapid iteration and optimization. This hybrid approach dramatically accelerates the discovery of hit compounds and their evolution into therapeutic candidates.
Why Combine AI with Experimental Screening?
- Speed & Scale: AI pre-filters immense virtual peptide libraries before wet-lab screening.
- Intelligent Design: Machine learning guides the incorporation of non-natural amino acids for enhanced stability and bioavailability.
- Closed-Loop Optimization: Experimental results feed back into AI models for continuous improvement.

Therapeutic Application Strategies
Leveraging hit peptides from our AI-enhanced platform for three distinct therapeutic modalities.

Peptide & Small Molecule Therapeutics
Starting from AI-validated hit peptides, we optimize pharmacological properties using structure-based design and non-natural amino acid incorporation. For oral delivery challenges, we leverage structural data to guide the conversion of peptides into small molecule mimetics via computational chemistry.
- Affinity & Selectivity Optimization
- Pharmacokinetic Tuning
- Small Molecule Mimetics

Peptide-Drug Conjugates
Our platform designs high-specificity carrier peptides for targeted delivery of diverse payloads: radionuclides, oligonucleotides, or cytotoxic agents. AI predicts conjugation sites and linker stability to optimize pharmacokinetics and minimize off-target effects.
- RI-PDCs for Imaging & Therapy
- Oligonucleotide Delivery
- Cytotoxic Payload Targeting

Multi-Functional Peptide Conjugates (MPCs)
By tethering peptides with different target specificities, we create multispecific therapeutics that address complex disease mechanisms. AI models predict optimal linker architectures and synergistic effects, enabling single-molecule combinations that act as bispecific or trispecific agents.
- Bispecific/Multispecific Designs
- Synergistic Mechanism Prediction
- Overcoming Drug Resistance
AI-Integrated Peptide Platform
Our platform combines three core engines to seamlessly integrate in silico design with wet-lab experimentation.

AI-Powered Library Design
Generative AI models trained on peptide-protein interaction data create focused libraries enriched for high binding affinity and structural diversity. These virtual libraries incorporate non-canonical amino acids and macrocyclic scaffolds, drastically reducing the experimental search space.
- Generative design of macrocyclic scaffolds
- Incorporation of non-natural amino acids
- Prediction of synthetic feasibility
AI Virtual Screening & Evolution
Deep learning models predict binding modes, affinities, and selectivities against target proteins. Hits are virtually evolved through iterative in silico mutagenesis, exploring sequence space that would be impossible to cover experimentally. Top candidates are then synthesized and screened via our automated mRNA display system.
- Affinity & selectivity prediction
- In silico directed evolution
- ADMET property forecasting


Integrated Wet-Lab Validation
AI-selected candidates are synthesized and screened using our high-throughput mRNA display platform. Binding data, structural information (X-ray, Cryo-EM), and functional assays are fed back into the AI models to refine predictions, creating a rapid closed-loop optimization cycle.
- Automated mRNA display screening
- Structural feedback (X-ray/Cryo-EM)
- Continuous model retraining
Why Choose Our AI-Peptide Platform?
Accelerating the discovery of next-generation peptide therapeutics through intelligent design and validation.
Collaboration Process
From target nomination to optimized lead series: a seamless partnership model.
Target & Strategy Consultation
We discuss your therapeutic goals, target biology, and desired modality (peptide, PDC, MPC) to define the optimal AI-driven discovery strategy.
AI Library Design & Virtual Screening
Our AI models generate focused virtual libraries and predict top hits. We refine predictions based on your input (e.g., desired properties, structural data).
Wet-Lab Validation
Top AI candidates are synthesized and screened via our automated mRNA display platform. Hits are confirmed, and binding kinetics/structural data are generated.
Iterative Optimization & Delivery
Experimental data feeds back into AI models for subsequent rounds. Optimized leads are characterized, and we deliver comprehensive reports for further development or partnership.
Deliverables & Cooperation Models
Flexible engagement tailored to your project stage and strategic goals.
What We Deliver
- AI-Predicted Hit Lists: Ranked candidates with binding predictions and structural models.
- Validated Hit Peptides: Experimentally confirmed binders with affinity/selectivity data.
- Optimized Lead Series: Structure-activity relationship (SAR) data from iterative cycles.
- Structural Data: Co-crystal or Cryo-EM structures of peptide-target complexes.
- IP Packages: Comprehensive data packages for patent filings.
Cooperation Models
- Targeted Discovery Projects: End-to-end service from hit finding to lead optimization for your specific target.
- Platform Access / FTE: Dedicated team of AI scientists and experimental biologists working as an extension of your R&D.
- Strategic Co-Development: Jointly develop peptide assets with shared IP and milestones.
- Technology Licensing: License our AI-peptide platform components for internal use.
Frequently Asked Questions
Common questions about our AI-driven cyclic peptide platform and partnership models.
Start Your AI-Peptide Project
Contact us today to discuss how our integrated platform can accelerate your peptide drug discovery.
Talk to our technical team about your project!
I Want To Talk